Cumulative evidence suggests that EZH2 was instrumental in conferring tumor cells with resistance to immune-mediated destruction, thereby underscoring the merit of prioritizing EZH2 as a target in immunotherapeutic strategies to potentially enhance treatment efficacy34. Here, EZH2 is linked to neoplasm.